閾剁墝浼氬憳绗?span style="font-size:1.5em;color:#f21">2骞滁/div> 璁块棶閲廁 3386165 缃戝潃:antibody.cnreagent.com 鍦ㄧ嚎鐣欒█
浜у搧鎼滅储
鎶椾綋 >> 鍏朵粬鎶椾綋
蹇冪7鑴傞叞鍩鸿浆绉婚叾1鎶椾綋
蹇冪7鑴傞叞鍩鸿浆绉婚叾1鎶椾綋鍥剧墖
浜よ揣鏈烔 1鍛?/span>
绱㈠彇璧勬枡鍙婃姤浠饵/span>
浜よ揣鏈烔 1鍛?/td>
浜у搧鍒悕: Anti-Lclat1
Anti-lysocardiolipin acyltransferase 1 Antibody
浜у搧浠嬬粛
闈舵爣锛欬p style="text-indent: 2em;">Lclat1


浜у搧鍒悕锛欬p style="text-indent: 2em;">1-AGPAT 8锛 AI181996锛 Agpat8锛 Alcat1锛 Gm91锛 Lycat锛 Lclat1锛 lysocardiolipin acyltransferase 1锛 lysocardiolipin acyltransferase 1锛 lysocardiolipin acyltransferase 1锛 1-AGP acyltransferase 8锛 1-acylglycerol-3-phosphate O-acyltransferase 8锛 acyl-CoA:lysocardiolipin acyltransferase 1锛 蹇冪7鑴傞叞鍩鸿浆绉婚叾1锛


鑳屾櫙淇℃伅锛欬div style="text-indent: 2em;">LYCAT is an acyl-CoA:lysocardiolipin acyltransferase. It possesses both lysophosphatidylinositol acyltransferase (LPIAT) and lysophosphatidylglycerol acyltransferase (LPGAT) activities. LYCAT recognizes both monolysocardiolipin and dilysocardiolipin as substrates with a preference for linoleoyl-CoA and oleoyl-CoA as acyl donors. LYCAT acts as a remodeling enzyme for cardiolipin, a major membrane polyglycerophospholipid. It converts lysophosphatidic acid (LPA) into phosphatidic acid (PA) with a relatively low activity. LYCAT is required for establishment of the hematopoietic and endothelial lineages.

瀹夸富锛歊bt
绫诲瀷锛歅ab
鍚岀鍨婜IgG
搴旂敤锛歐B
绾寲鏂瑰紡锛氫翰鍜岀函鍖朁br/>鍋惰仈鐗╋細Unconjugated
鎬х姸锛氭恫浣
瀛樺偍婧舵恫锛氬弬闃呰鏄庝功
娴撳害锛欱atch dependent (Please refer to the vial label for the specific concentration.)
绋€閲婃瘮渚婜 Optimal dilutions/concentrations should be determined by the end user
鍌ㄥ瓨锛氱粡甯镐娇鐢ㄥ垯4掳C淇濆瓨銆?20掳C淇濆瓨涓嶈秴杩囦袱骞淬€傞伩鍏嶅弽澶嶅喕铻嶃€侟br/>娉ㄦ剰浜嬮」锛氫粎渚涘疄楠屽浣跨敤銆備笉閫傜敤浜庝汉绫绘垨鍔ㄧ墿鐨勪换浣曚复搴婏紝娌荤枟鎴栬瘖鏂敤閫斻€備笉閫傚悎鍔ㄧ墿鎴栦汉绫婚鐢ㄣ€侟/p>

鐩稿叧浜у搧
Baidu
map